|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30 SEK | +0.67% |
|
-6.25% | -16.20% |
Redeye shares its thoughts on the Phase 1a clinical trials and the recently published topline data from the renal impairment study. We also discuss the revamped management team, recent rights issue and what we see for
Read more and download the Research Update
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source
| 1st Jan change | Capi. | |
|---|---|---|
| -16.20% | 27.49M | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.53% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
GUARD THERAPEUTICS INTERNATIONAL AB 
